Do Diabetic Foot Infections With Methicillin-Resistant Staphylococcus aureus Differ From Those With Other Pathogens?

被引:53
|
作者
Zenelaj, Besa [1 ,2 ]
Bouvet, Cindy [1 ,2 ]
Lipsky, Benjamin A. [1 ,2 ,3 ]
Uckay, Ilker [1 ,2 ]
机构
[1] Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland
[2] Fac Med, Geneva, Switzerland
[3] Univ Oxford, Oxford, England
来源
INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS | 2014年 / 13卷 / 04期
关键词
diabetic foot infection; Staphylococcus aureus; MRSA; review; treatment; RISK-FACTORS; SOFT-TISSUE; MICROBIAL PROFILE; CLINICAL-OUTCOMES; TREATMENT FAILURE; COMPLICATED SKIN; ULCERS; VANCOMYCIN; OSTEOMYELITIS; PREVALENCE;
D O I
10.1177/1534734614550311
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
There is controversy as to whether or not diabetic foot infections (DFIs) caused by methicillin-resistant Staphylococcus aureus (MRSA) are associated with worse outcomes than DFIs caused by other pathogens. To address this issue we performed a nonsystematic literature search of published articles in English language journals seeking studies reporting on the outcomes of DFIs related to their microbiology. We retrieved 48 articles published from 1999 to 2013 that described a total of 7771 cases of DFI. The overall proportion of DFIs with an isolate of S aureus was about 30%; just over one third of these (11% of all cases) were MRSA strains. Among the DFI cases caused by MRSA 1543 were episodes of soft tissue infections and 113 of osteomyelitis, while non-MRSA organisms caused 5761 soft tissue infections and 354 cases of osteomyelitis. Only 5 of the included articles attempted a comparison between DFI caused by MRSA and those caused by other pathogens, with no clear differences noted. The median total duration of antibiotic therapy for DFI caused by MRSA was 26 days, of which a median of 10 days was given intravenously. Only a few articles reported the proportion of patients with a recurrence, but they often did not differentiate between MRSA and non-MRSA cases. Four publications reported a worse functional or microbiological outcome in MRSA, compared to non-MRSA, cases, but the findings were variable and differences did not seem to be significant. Many trials failed to adjust for case-mix or to definitively demonstrate a relationship between microbiology and outcomes. Few of the articles specifically commented on whether the MRSA isolates were health care- or community-acquired strains. Notwithstanding the substantial limitations of the available literature, there does not appear to be a need for any special treatment for DFI caused by MRSA. The current guidelines for treating according to established international recommendations seem appropriate.
引用
收藏
页码:263 / 272
页数:10
相关论文
共 50 条
  • [41] Role of methicillin-resistant Staphylococcus aureus in head and neck infections
    Brook, I.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2009, 123 (12): : 1301 - 1307
  • [42] Bacteremia due to Methicillin-Resistant Staphylococcus aureus New Therapeutic Approaches
    Holubar, Marisa
    Meng, Lina
    Deresinski, Stan
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2016, 30 (02) : 491 - +
  • [43] Risk factors for methicillin-resistant Staphylococcus aureus and extended-spectrum β-lactamase-producing Enterobacterales in patients with diabetic foot infections requiring hospital admission
    Garcia Zafra, Victoria
    Hernandez Torres, Alicia
    Garcia Vazquez, Elisa
    Soria Cogollos, Teresa
    Canteras Jordana, Manuel
    Ruiz Gomez, Joaquin
    Gomez Gomez, Joaquin
    Hernandez Martinez, Antonio
    Barberan, Jose
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2020, 33 (06) : 430 - 435
  • [44] Epidemiology of Methicillin-Resistant Staphylococcus aureus Diabetic Foot Infections in a Large Academic Hospital: Implications for Antimicrobial Stewardship
    Reveles, Kelly R.
    Duhon, Bryson M.
    Moore, Robert J.
    Hand, Elizabeth O.
    Howell, Crystal K.
    PLOS ONE, 2016, 11 (08):
  • [45] New treatments for methicillin-resistant Staphylococcus aureus
    Stryjewski, Martin E.
    Corey, G. Ralph
    CURRENT OPINION IN CRITICAL CARE, 2009, 15 (05) : 403 - 412
  • [46] Antimicrobial therapy for methicillin-resistant Staphylococcus aureus
    Choo, Eun Ju
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2018, 61 (03): : 207 - 213
  • [47] Methicillin-Resistant Staphylococcus aureus Infection in Septorhinoplasty
    Angelos, Patrick C.
    Wang, Tom D.
    LARYNGOSCOPE, 2010, 120 (07): : 1309 - 1311
  • [48] Polymicrobial methicillin-resistant Staphylococcus aureus bloodstream infections
    Escalona, Angelica
    Hayashi, Emi
    Evans, Michelle
    van Bakel, Harm
    Alburquerque, Bremy
    Dupper, Amy C.
    McBride, Russell
    Altman, Deena R.
    MICROBIOLOGY SPECTRUM, 2024, 12 (11):
  • [49] Pediatric Methicillin-Resistant Staphylococcus aureus Osteoarticular Infections
    Kaushik, Ashlesha
    Kest, Helen
    MICROORGANISMS, 2018, 6 (02)
  • [50] Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections
    Shime, Nobuaki
    Saito, Nobuyuki
    Bokui, Miya
    Sakane, Naoki
    Kamimura, Mitsuhiro
    Shinohara, Tsutomu
    Kosaka, Tadashi
    Ishikura, Hisashi
    Kobayashi, Atsuko
    INFECTION AND DRUG RESISTANCE, 2018, 11 : 1073 - 1081